Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine

Virology

Volumn 352, Issue 2, 2006, Pages 285-294

  Robinson, Harriet L ^a,b   Montefiori, David C ^c   Villinger, Francois ^a,b   Robinson, James E ^d   Sharma, Sunita ^a,b   Wyatt, Linda S ^e   Earl, Patricia L ^e   McClure, Harold M ^b   Moss, Bernard ^e   Amara, Rama Rao ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Avidity of Ab; DNA MVA vaccine; GM CSF DNA adjuvant; Immunodeficiency virus vaccine; Neutralizing Ab; Re emergent virus protection

Indexed keywords

ANTIGEN; ANTISERUM; DNA VACCINE; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; POL PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ADJUVANT THERAPY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODY AFFINITY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HIV ANTIBODIES; HIV-1; MACACA MULATTA; NEUTRALIZATION TESTS; T-LYMPHOCYTES; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33747040210     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.02.011     Document Type: Article

References (57)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.-L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a Mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
2. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., O'Neil S.P., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McNicholl J.M., McClure H.M., Moss B., and Robinson H.L. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76 12 (2002) 6138-6146
3. Amara R.R., Villinger F., Staprans S., Altman J.D., Montefiori D., Kozyr N.L., Xu Y., Wyatt L., Earl P.L., Herndon J.G., McClure H.M., Moss B., and Robinson H.L. Different patterns of immune responses but similar control of a mucosal immunodeficiency virus challenge by MVA and DNA/MVA vaccines. J. Virol. 76 (2002) 7625-7631
4. Amara R.R., Ibegbu C., Villinger F., Montefiori D.C., Sharma S., Nigam P., Xu Y., McClure H.M., and Robinson H.L. Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA-vaccinated macaques. Virology 343 2 (2005) 246-255
5. Ardavin C., Martinez del Hoyo G., Martin P., Anjuere F., Arias C.F., Marin A.R., Ruiz S., Parrillas V., and Hernandez H. Origin and differentiation of dendritic cells. Trends Immunol. 22 12 (2001) 691-700
6. Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., Jackson S.S., Lifton M.A., Freed D.C., Perry H.C., Davies M.E., Shiver J.W., and Letvin N.L. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J. Immunol. 168 2 (2002) 562-568
7. Breitfeld D., Ohl L., Kremmer E., Ellwart J., Sallusto F., Lipp M., and Forster R. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192 11 (2000) 1545-1552
8. Buge S.L., Ma H.L., Amara R.R., Wyatt L.S., Earl P.L., Villinger F., Montefiori D.C., Staprans S.I., Xu Y., Carter E., O'Neil S.P., Herndon J.G., Hill E., Moss B., Robinson H.L., and McNicholl J.M. Gp120-Alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res. Hum. Retrovir. 19 10 (2003) 891-900
9. Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K.M., Tartaglia J., Caudrelier P., El Habib R., Klein M., Lazzarin A., Stablein D.M., Deers M., Corey L., Greenberg M.L., Schwartz D.H., and Montefiori D.C. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 16 18 (2000) 2019-2035
10. Burton D.R. A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. U.S.A. 94 19 (1997) 10018-10023
11. Burton D.R., Stanfield R.L., and Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U.S.A. 102 42 (2005) 14943-14948
12. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., and Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300 5628 (2003) 2065-2071
13. Carotenuto P., Looij D., Keldermans L., de Wolf F., and Goudsmit J. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12 13 (1998) 1591-1600
14. Cheng L., Ziegelhoffer P.R., and Yang N.S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc. Natl. Acad. Sci. U.S.A. 90 10 (1993) 4455-4459
15. Clements J.E., Montelaro R.C., Zink M.C., Amedee A.M., Miller S., Trichel A.M., Jagerski B., Hauer D., Martin L.N., and Bohm R.P. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 69 5 (1995) 2737-2744
16. Coates P.T., Barratt-Boyes S.M., Zhang L., Donnenberg V.S., O'Connell P.J., Logar A.J., Duncan F.J., Murphey-Corb M., Donnenberg A.D., Morelli A.E., Maliszewski C.R., and Thomson A.W. Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand. Blood 102 7 (2003) 2513-2521
17. Cole K.S., Rowles J.L., Jagerski B.A., Murphey-Corb M., Unangst T., Clements J.E., Robinson J., Wyand M.S., Desrosiers R.C., and Montelaro R.C. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol. 71 7 (1997) 5069-5079
18. Daro E., Pulendran B., Brasel K., Teepe M., Pettit D., Lynch D.H., Vremec D., Robb L., Shortman K., McKenna H.J., Maliszewski C.R., and Maraskovsky E. Polyethylene glycol-modified GM-CSF expands CD11b (high) CD11c (high) but not CD11b (low) CD11c (high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 165 1 (2000) 49-58
19. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., Grossman Z., Dybul M., Oxenius A., Price D.A., Connors M., and Koup R.A. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 6884 (2002) 95-98
20. Etemad-Moghadam B., Karlsson G.B., Halloran M., Sun Y., Schenten D., Fernandes M., Letvin N.L., and Sodroski J. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J. Virol. 72 10 (1998) 8437-8445
21. Etemad-Moghadam B., Rhone D., Steenbeke T., Sun Y., Manola J., Gelman R., Fanton J.W., Racz P., Tenner-Racz K., Axthelm M.K., Letvin N.L., and Sodroski J. Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J. Virol. 75 12 (2001) 5646-5655
22. Geissler M., Gesien A., Tokushige K., and Wands J.R. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J. Immunol. 158 3 (1997) 1231-1237
23. Haddad D., Ramprakash J., Sedegah M., Charoenvit Y., Baumgartner R., Kumar S., Hoffman S.L., and Weiss W.R. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J. Immunol. 165 7 (2000) 3772-3781
24. Hofmann-Lehmann R., Swenerton R.K., Liska V., Leutenegger C.M., Lutz H., McClure H.M., and Ruprecht R.M. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res. Hum. Retrovir. 16 13 (2000) 1247-1257
25. Horton H., Vogel T.U., Carter D.K., Vielhuber K., Fuller D.H., Shipley T., Fuller J.T., Kunstman K.J., Sutter G., Montefiori D.C., Erfle V., Desrosiers R.C., Wilson N., Picker L.J., Wolinsky S.M., Wang C., Allison D.B., and Watkins D.I. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76 14 (2002) 7187-7202
26. Hutchinson K.L., Villinger F., Miranda M.E., Ksiazek T.G., Peters C.J., and Rollin P.E. Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype). J. Med. Virol. 65 3 (2001) 561-566
27. Kamath A.T., Hanke T., Briscoe H., and Britton W.J. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. Immunology 96 4 (1999) 511-516
28. Karlsson G.B., Halloran M., Li J., Park I.W., Gomila R., Reimann K.A., Axthelm M.K., Iliff S.A., Letvin N.L., and Sodroski J. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J. Virol. 71 6 (1997) 4218-4225
29. Kumar S., Villinger F., Oakley M., Aguiar J.C., Jones T.R., Hedstrom R.C., Gowda K., Chute J., Stowers A., Kaslow D.C., Thomas E.K., Tine J., Klinman D., Hoffman S.L., and Weiss W.W. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor. Immunol. Lett. 81 1 (2002) 13-24
30. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., and Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 6916 (2002) 678-682
31. Lee S.W., Cho J.H., and Sung Y.C. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J. Virol. 72 10 (1998) 8430-8436
32. Letvin N.L. Progress toward an HIV vaccine. Annu. Rev. Med. 56 (2005) 213-223
33. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
34. Mackay C.R. Follicular homing T helper (Th) cells and the Th1/Th2 paradigm. J. Exp. Med. 192 11 (2000) F31-F34
35. McKay P.F., Barouch D.H., Santra S., Sumida S.M., Jackson S.S., Gorgone D.A., Lifton M.A., and Letvin N.L. Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur. J. Immunol. 34 4 (2004) 1011-1020
36. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV and SHIV in a luciferase reporter gene assay. In: Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W., and Coico R. (Eds). Current Protocols in Immunology (2004), John Wiley and Sons, New York 12.11.1-12.11.15
37. Montefiori D.C., Robinson Jr. W.E., Schuffman S.S., and Mitchell W.M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26 2 (1988) 231-235
38. Montefiori D.C., Reimann K.A., Wyand M.S., Manson K., Lewis M.G., Collman R.G., Sodroski J.G., Bolognesi D.P., and Letvin N.L. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J. Virol. 72 4 (1998) 3427-3431
39. Moog C., Fleury H.J., Pellegrin I., Kirn A., and Aubertin A.M. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J. Virol. 71 5 (1997) 3734-3741
40. Parren P.W., and Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77 (2001) 195-262
41. Parren P.W., Mondor I., Naniche D., Ditzel H.J., Klasse P.J., Burton D.R., and Sattentau Q.J. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72 5 (1998) 3512-3519
42. Pasquini S., Xiang Z., Wang Y., He Z., Deng H., Blaszczyk-Thurin M., and Ertl H.C. Cytokines and costimulatory molecules as genetic adjuvants. Immunol. Cell Biol. 75 4 (1997) 397-401
43. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., Bolognesi D.P., Fauci A.S., and Montefiori D.C. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 176 4 (1997) 924-932
44. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.W., Karlsson G.B., Sodroski J., and Letvin N.L. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70 10 (1996) 6922-6928
45. Reimann K.A., Li J.T., Voss G., Lekutis C., Tenner-Racz K., Racz P., Lin W., Montefiori D.C., Lee-Parritz D.E., Lu Y., Collman R.G., Sodroski J., and Letvin N.L. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70 5 (1996) 3198-3206
46. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U.S.A. 100 7 (2003) 4144-4149
47. Robinson H.L. New hope for an AIDS vaccine. Nat. Rev., Immunol. 2 (2002) 239-250
48. Rogers W.O., Weiss W.R., Kumar A., Aguiar J.C., Tine J.A., Gwadz R., Harre J.G., Gowda K., Rathore D., Kumar S., and Hoffman S.L. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect. Immun. 70 8 (2002) 4329-4335
49. Schaerli P., Willimann K., Lang A.B., Lipp M., Loetscher P., and Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192 11 (2000) 1553-1562
50. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat. Rev., Immunol. 2 3 (2002) 151-161
51. Sin J.I., Kim J.J., Ugen K.E., Ciccarelli R.B., Higgins T.J., and Weiner D.B. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur. J. Immunol. 28 11 (1998) 3530-3540
52. Wang R., Richie T.L., Baraceros M.F., Rahardjo N., Gay T., Banania J.G., Charoenvit Y., Epstein J.E., Luke T., Freilich D.A., Norman J., and Hoffman S.L. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect. Immun. 73 5 (2005) 2863-2872
53. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 6929 (2003) 307-312
54. Weiss W.R., Ishii K.J., Hedstrom R.C., Sedegah M., Ichino M., Barnhart K., Klinman D.M., and Hoffman S.L. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol. 161 5 (1998) 2325-2332
55. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., and Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein [see comments]. Nature 393 6686 (1998) 705-711
56. Xiang Z., and Ertl H.C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2 2 (1995) 129-135
57. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev., Immunol. 4 3 (2004) 199-210